Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hereditary angioedema patients would prefer newer-generation oral prophylaxis
Daniela Geba, Johan Mohd Sani, Michaela Gascon, et al.
Journal of Drug Assessment (2020) Vol. 10, Iss. 1, pp. 51-56
Open Access | Times Cited: 18

Showing 18 citing articles:

Oral Edaravone – Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis
Gary L. Pattee, Angela Genge, Philippe Couratier, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 10, pp. 859-866
Open Access | Times Cited: 16
Managing Diagnosis, Treatment, and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor
Douglas H. Jones, Heidi Zafra, John Anderson
Journal of Asthma and Allergy (2023) Vol. Volume 16, pp. 447-460
Open Access | Times Cited: 13
Global Frequency, Diagnosis, and Treatment of Hereditary Angioedema with Normal C1 Inhibitor
Markus Magerl, Marc A. Riedl, L. Karla Arruda, et al.
Journal of Allergy and Clinical Immunology Global (2025) Vol. 4, Iss. 3, pp. 100446-100446
Open Access
The multifactorial impact of receiving a hereditary angioedema diagnosis
Jason Raasch, Mark C. Glaum, Maeve O’Connor
World Allergy Organization Journal (2023) Vol. 16, Iss. 6, pp. 100792-100792
Open Access | Times Cited: 9
Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs
Laurence Bouillet, O. Fain, G. Armengol, et al.
Allergy and Asthma Proceedings (2022) Vol. 43, Iss. 5, pp. 406-412
Closed Access | Times Cited: 13
Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks
Raffi Tachdjian, Sinisa Savic, Moshe Fridman, et al.
Allergy and Asthma Proceedings (2023) Vol. 45, Iss. 1, pp. 37-43
Closed Access | Times Cited: 8
Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia
Alexander Troelnikov, Karen Milburn, Pravin Hissaria, et al.
World Allergy Organization Journal (2024) Vol. 17, Iss. 7, pp. 100918-100918
Open Access | Times Cited: 2
Current challenges and future opportunities in patient‐focused management of hereditary angioedema: A narrative review
Anete Sevciovic Grumach, Noga Gadir, Aharon Kessel, et al.
Clinical and Translational Allergy (2023) Vol. 13, Iss. 5
Open Access | Times Cited: 6
An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy
William R. Lumry, Jonathan A. Bernstein, Henry H. Li, et al.
Allergy and Asthma Proceedings (2023) Vol. 45, Iss. 1, pp. 44-49
Closed Access | Times Cited: 6
Advent of oral medications for the treatment of hereditary angioedema
Anna Valerieva, Teresa Caballero, Markus Magerl, et al.
Clinical and Translational Allergy (2024) Vol. 14, Iss. 9
Open Access | Times Cited: 1
CU06‐1004 alleviates vascular hyperpermeability in a murine model of hereditary angioedema by protecting the endothelium
Sunghye Lee, Yeomyeong Kim, Ye‐Seul Kim, et al.
Allergy (2023) Vol. 78, Iss. 5, pp. 1333-1346
Open Access | Times Cited: 2
Quantifying the Value of Introducing an Oral Drug Delivery Option for Edaravone: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations
Naoko Ronquest, Kyle Paret, Aaron Lucas, et al.
ClinicoEconomics and Outcomes Research (2022) Vol. Volume 14, pp. 499-511
Open Access | Times Cited: 3
Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat
Marc A. Riedl, Daniel Soteres, J. Wesley Sublett, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 4, pp. 505-511.e1
Closed Access | Times Cited: 1
Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial
Daisuke Honda, Michihiro Hide, Tomoo Fukuda, et al.
World Allergy Organization Journal (2024) Vol. 17, Iss. 3, pp. 100882-100882
Open Access
Transitioning Patients From Second- to First-Line Prophylaxis in Hereditary Angioedema
Caroline E. Cross
European Medical Journal (2024), pp. 22-27
Open Access
Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series
C. Hoarau, Alireza Maleki, Laurence Bouillet, et al.
Orphanet Journal of Rare Diseases (2024) Vol. 19, Iss. 1
Open Access
Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
Daniel Soteres, Fellicia Grimes
Clinical Case Reports (2021) Vol. 9, Iss. 11
Open Access | Times Cited: 3
Hereditary Angioedema Management: Individualization
Kristin Epland, Melanie C. Wayne, H. Von Pein
The Journal for Nurse Practitioners (2021) Vol. 17, Iss. 10, pp. 1199-1203
Closed Access
Page 1

Scroll to top